Next Article
Novavax's combined COVID-Flu vaccine shows promise
Novavax just shared some good news: their new vaccine that tackles both COVID-19 and the flu did well in a late-stage trial with about 2,000 participants. The strong immune response was observed in adults aged 65 and older. The combined shot helped people build strong immunity—about as good as what you'd get from current vaccines—and no new safety issues popped up.
Novavax is also developing traditional protein-based COVID-19 vaccine
With these results, Novavax is gearing up for more studies to get the green light from regulators. They're also teaming up with Sanofi in a $1.2 billion deal to keep developing their traditional protein-based COVID-19 vaccine, Nuvaxovid—a solid alternative if you prefer something different from the usual mRNA shots like Pfizer or Moderna.